Our finding suggests that, besides primary radiotherapy, some other supplementary treatment, such as hypoxia-modifying and gene targeted therapy, should be considered for NPC patients showing high HIF-1α or CAIX expression. This evidence concerns the gene CA9 and nasopharyngeal carcinoma.